Assembly Biosciences reported Q1 2026 results highlighting progress in its viral disease drug pipeline, including completion of Phase 1b studies for herpes treatments ABI-5366 and ABI-1179, and chronic toxicology studies for hepatitis delta candidate ABI-6250. The company expects to start Phase 2 trials for ABI-6250 by Q4 2026 and will decide mid-year whether to opt into a cost-profit share deal with Gilead for the herpesvirus program. Financially, Assembly Biosciences holds $226.6 million in cash and securities, with a net loss of $9.1 million for the quarter, and projects funding into 2028. These developments position the company to advance treatments for serious viral infections while managing collaboration with Gilead.
Lowey Dannenberg, P.C. is investigating Hims & Hers Health, Inc. for allegedly sharing sensitive user health data, including medical histories and mental health info, with third parties without proper consent. This raises concerns about violations of...
Digital agency 9thCO completed a major digital transformation for DNRS, moving from a fragmented WordPress setup to a unified composable architecture. This upgrade centralizes user management, integrates key business tools like CRM and scheduling, an...
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
